News

Brand Change Announcement: AegirBio AB has officially changed its name to Magnasense AB. The new website, www.magnasense.com, launched on 9 July 2024, with redirects from www.aegirbio.com.

Aegirbios VD Martin Linde intervjuad av BioStock

Följ länken nedan för artikeln
biostock.se/2020/06/aegirbios-matteknik-kan-spara-mangmiljardbelopp

All news Regulatory news Non-regulatory news regulatory

15 November 2024 - (Only in Swedish) Magnasense Interim Report July - September 2024

15 November 2024 - (Only in Swedish) Magnasense Delårsrapport Juli - September 2024

05 November 2024 - (Only in Swedish) Magnasense AB carries out previously announced directed share issue of 13,090,908 shares to Atlas Special Opportunities following called upon conversions of SEK 3.00 million

05 November 2024 - (Only in Swedish) Magnasense AB genomför tidigare aviserad riktad nyemission om 13 090 908 aktier till Atlas Special Opportunities med anledning av påkallade konverteringar om totalt 3,00 MSEK

31 October 2024 - (Only in Swedish) Magnasense avser genomföra riktad emission till Atlas Special Opportunities med anledning av påkallade konverteringar om totalt 3,00 MSEK

31 October 2024 - (Only in Swedish) Magnasense intends to carry out a directed issue to Atlas Special Opportunities due to called on conversions totalling SEK 3.00 million

26 September 2024 - (Only in Swedish) Magnasense upptar lån om totalt 3 MSEK från styrelseledamöter

26 September 2024 Magnasense obtain loans of totaling MSEK 3 from board members

20 September 2024 - (Only in Swedish) Magnasense AB påkallar utbetalning av del av Tranch 3 om 2,50 MSEK från Atlas Special Opportunities, LLC

20 September 2024 Magnasense AB calls for partial payment of Tranche 3 of SEK 2.50 million from Atlas Special Opportunities, LLC

17 September 2024 - (Only in Swedish) Magnasense AB genomför tidigare aviserad riktad nyemission om 7 080 627 aktier till Atlas Special Opportunities med anledning av påkallade konverteringar om totalt 2,50 MSEK

17 September 2024 Magnasense AB carries out previously announced directed share issue of 7,080,627 shares to Atlas Special Opportunities following called upon conversions of SEK 2.50 million

14 September 2024 - (Only in Swedish) Magnasense intends to carry out a directed issue to Atlas Special Opportunities due to called on conversions totalling SEK 2.50 million

14 September 2024 - (Only in Swedish) Magnasense avser genomföra riktad emission till Atlas Special Opportunities med anledning av påkallade konverteringar om totalt 2,50 MSEK

12 September 2024 - (Only in Swedish) Magnasense lämnar in patentansökan

12 September 2024 Magnasense files a patent application

11 September 2024 - (Only in Swedish) Magnasense följer planen i RADx-projektet

11 September 2024 Magnasense on track in RADx project

29 August 2024 Magnasense and Salignostics Initiate Feasibility Study Project

29 August 2024 - (Only in Swedish) Magnasense och Salignostics inleder förstudieprojekt

25 August 2024 MAGNASENSE AB EXTENDS THE PAYMENT PERIOD FOR BUSINESS-CRITICAL SUPPLIER INVOICES TOTALLING USD 970,000 AND DECIDES ON A DIRECTED ISSUE

25 August 2024 - (Only in Swedish) MAGNASENSE AB FÖRLÄNGER BETALNINGSFRISTEN FÖR AFFÄRSKRITISKA LEVERANTÖRSFAKTUROR OM SAMMANLAGT USD 970 000 OCH BESLUTAR OM EN RIKTAD NYEMISSION

23 August 2024 - (Only in Swedish) Magnasense delårsrapport april – juni 2024

23 August 2024 Magnasense interim report April – June 2024

31 July 2024 - (Only in Swedish) Magnasense utser Vicki Johnson till tillförordnad finanschef

31 July 2024 Magnasense appoints Vicki Johnson as interim CFO

18 July 2024 - (Only in Swedish) Magnasense AB påkallar utbetalning av del av Tranche 3 om 2,50 MSEK från Atlas Special Opportunities, LLC

18 July 2024 Magnasense AB calls for partial payment of Tranche 3 of SEK 2.50 million from Atlas Special Opportunities, LLC

09 July 2024 Magnasense AB carries out previously announced directed share issue of 6,115,662 shares to Atlas Special Opportunities following called upon conversions of SEK 2.50 million

09 July 2024 - (Only in Swedish) Magnasense AB genomför tidigare aviserad riktad nyemission om 6 115 662 aktier till Atlas Special Opportunities med anledning av påkallade konverteringar om totalt 2,50 MSEK

08 July 2024 - (Only in Swedish) AegirBio AB byter namn till Magnasense AB

08 July 2024 AegirBio AB changes name to Magnasense AB

08 July 2024 Melissa Grant joins AegirBio Scientific Advisory Board

08 July 2024 - (Only in Swedish) Melissa Grant ny medlem i AegirBios vetenskapliga råd

01 July 2024 - (Only in Swedish) AegirBio avser genomföra riktad emission till Atlas Special Opportunities med anledning av påkallade konverteringar om totalt 2,50 MSEK

28 June 2024 - (Only in Swedish) Kommuniké från årsstämma i AegirBio AB (publ) den 28 juni 2024

27 June 2024 - (Only in Swedish) AegirBio AB har erhållit utbetalning av Tranche 2 om 5,00 MSEK från Atlas Special Opportunities, LLC

27 June 2024 AegirBio AB has received payment of Tranche 2 of SEK 5.00 million from Atlas Special Opportunities, LLC

11 June 2024 - (Only in Swedish) AegirBio erhåller ytterligare milstolpsbetalning under RadX NIH

11 June 2024 AegirBio receives second milestone payment under RadX NIH

04 June 2024 - (Only in Swedish) AegirBio tillkännager strategiskt namnbyte till MagnOral AB

04 June 2024 AegirBio announces strategic name change to MagnOral AB

31 May 2024 - (Only in Swedish) AEGIRBIO AB publicerar årsredovisning och revisionsberättelse för räkenskapsåret 2023

30 May 2024 - (Only in Swedish) AegirBio AB genomför tidigare aviserad riktad nyemission om 5 175 374 aktier motsvarande cirka 2,54 MSEK till Atlas Special Opportunities samt påkallar utbetalning av Tranche 2

30 May 2024 - (Only in Swedish) AegirBio AB carries out previously announced directed share issue of 5,175,374 shares corresponding to approximately SEK 2.54 million to Atlas Special Opportunities and calls for payment of Tranche 2

30 May 2024 - (Only in Swedish) Kallelse till årsstämma i AegirBio AB (publ)

29 May 2024 - (Only in Swedish) AegirBios VD Marco Witteveen deltar i SalivaDirects 3:e årliga konferens i Washington, DC, 5-7 juni 2024

29 May 2024 - (Only in Swedish) AegirBio’s CEO Marco Witteveen to Attend SalivaDirect's 3rd Annual Conference in Washington, DC, June 5-7, 2024

21 May 2024 - (Only in Swedish) AEGIRBIO AB SLUTFÖR FRAMGÅNGSRIKT YTTERLIGARE EN MILSTOLPE I RADx® TECH-PROGRAMMET

21 May 2024 - (Only in Swedish) AEGIRBIO AB SUCCESSFULLY COMPLETES AN ADDITIONAL MILESTONE OF RADx® TECH PROGRAM

17 May 2024 - (Only in Swedish) AegirBio avger delårsrapport och redogör för väsentliga händelser

16 May 2024 - (Only in Swedish) AEGIRBIO-studie publicerad i tidskriften Multiple Sclerosisand Related Disorders

16 May 2024 - (Only in Swedish) AEGIRBIO study published in Multiple Sclerosis and Related Disorders journal

13 May 2024 - (Only in Swedish) AegirBio AB påkallar utbetalning av Tranche 1 om 7,50 MSEK samt avser genomföra riktad kvittningsemission av 5 175 374 aktier till Atlas Special Opportunities, LLC

13 May 2024 - (Only in Swedish) AegirBio AB calls for payment of Tranche 1 of SEK 7.50 million and intends to carry out a directed set-off issue of 5,175,374 shares to Atlas Special Opportunities, LLC

08 May 2024 - (Only in Swedish) AEGIRBIO erhåller milstolpsbetalning under RadX NIH

08 May 2024 - (Only in Swedish) AEGIRBIO Receives Milestone Payment under RadX NIH

30 April 2024 - (Only in Swedish) AEGIRBIO AB GÖR YTTERLIGARE FRAMSTEG OCH SLUTFÖR MILSTOLPE "TILLGÄNGLIGHET" I RADx® TECH-PROGRAMMET

30 April 2024 - (Only in Swedish) AEGIRBIO AB ADVANCES FURTHER WITH “ACCESSIBILITY” MILESTONE COMPLETION IN RADx® TECH PROGRAM

26 April 2024 - (Only in Swedish) Kommuniké från extra bolagsstämma i AegirBio AB (publ) den 26 april 2024

18 April 2024 - (Only in Swedish) AegirBio AB:s dotterbolag påkallar skiljeförfarande mot Salofa Oy

18 April 2024 - (Only in Swedish) AegirBio AB's subsidiary initiates arbitration against Salofa Oy

09 April 2024 - (Only in Swedish) Kallelse till extra bolagsstämma i AegirBio AB (publ)

09 April 2024 - (Only in Swedish) AegirBios styrelseordförande har meddelat sin avsikt att lämna styrelsen

09 April 2024 AegirBio’s chairman has announced his intention to leave the board of directors

09 April 2024 - (Only in Swedish) AegirBio ingår villkorat avtal om en lånefacilitet på 45 MSEK med Atlas Special Opportunities och ett avtal om ändring av villkor för utestående konvertibler, att godkännas av en extra bolagsstämma

09 April 2024 AegirBio enters into a conditional agreement on a MSEK 45 loan facility with Atlas Special Opportunities and an agreement to amend the outstanding convertible bonds, subject to EGM approval

29 March 2024 - (Only in Swedish) AEGIRBIO AVGER BOKSLUTSKOMMUNIKÉ OCH REDOGÖR FÖR VÄSENTLIGA HÄNDELSER

08 March 2024 - (Only in Swedish) Finansinspektionen begär yttrande från AegirBio AB

27 February 2024 - (Only in Swedish) Aegirbio utökar sitt Scientific Advisory Board inom oral hälsa med professor Iain L.C. Chapple

27 February 2024 Aegirbio Expands Oral Health Scientific Advisory Board with Professor Iain L.C. Chapple

24 January 2024 Renowned Gastroenterologist, Dr. Adam S. Cheifetz, Joins AegirBio’s Scientific Advisory Board

20 December 2023 AegirBio AB: Atlas Special Opportunities, LLC calls for partial conversion of outstanding convertible bonds to a nominal amount of MSEK 5.00

20 December 2023 - (Only in Swedish) AegirBio AB: Atlas Special Opportunities, LLC påkallar partiell konvertering av utestående konvertibler till ett nominellt belopp om 5,00 MSEK

24 November 2023 - (Only in Swedish) AegirBio avger delårsrapport och redogör för väsentliga händelser

03 November 2023 - (Only in Swedish) AegirBio AB utser Christel Dahlberg till CFO

01 November 2023 AegirBio AB Receives $239,547 award from the National Institutes of Health RADx Tech Program

01 November 2023 AegirBio focuses on RadX project, will not uphold CE-markings for the MagniaReader TDM tests

30 October 2023 Interview with AegirBio CEO Mr Marco Witteveen

09 October 2023 AegirBio promotes Dr. Vasiliki Fragkou to Chief Operating Officer from November 1, 2023.

06 October 2023 AEGIRBIO RECEIVES $1.2 MILLION NIH AWARD

28 September 2023 - (Only in Swedish) AegirBio publish video presentation by CEO Marco Witteveen

25 August 2023 - (Only in Swedish) Kommuniké från fortsatt årsstämma i AegirBio AB (publ) den 25 augusti 2023

25 August 2023 - (Only in Swedish) AegirBio avger delårsrapport och redogör för väsentliga händelser

24 July 2023 - (Only in Swedish) Kallelse till fortsatt årsstämma i AegirBio AB (publ)

21 July 2023 - (Only in Swedish) AegirBio AB publicerar årsredovisning och revisionsberättelse för räkenskapsåret 2022

21 July 2023 - (Only in Swedish) Rättelse: AEGIRBIO AVGER DELÅRSRAPPORT OCH REDOGÖR FÖR VÄSENTLIGA HÄNDELSER

17 July 2023 - (Only in Swedish) AegirBio AB har fått programmatiskt godkännande av National Institutes of Health (NIH) för ett tillgänglighetsprojekt

17 July 2023 - (Only in Swedish) AegirBio AB has received National Institutes of Health (NIH) programmatic approval for an accessibility project

14 July 2023 - (Only in Swedish) AegirBio senarelägger publiceringen av årsredovisningen för räkenskapsåret 2022

07 July 2023 - (Only in Swedish) Aegirbio sluter avtal med Salofa för veterinärmarknaden och får en första order på c:a 2 miljoner kronor

07 July 2023 - (Only in Swedish) Aegirbio signs agreement with Salofa for the veterinary market and receives a first order worth approximately SEK 2 million.

30 June 2023 - (Only in Swedish) Kommuniké från årsstämma i AegirBio AB (publ) den 30 juni 2023

29 June 2023 - (Only in Swedish) AegirBio senarelägger publiceringen av årsredovisningen för räkenskapsåret 2022

17 June 2023 - (Only in Swedish) Rättelse: Nils Paulsson lämnar rollen som COO

17 June 2023 - (Only in Swedish) Nils Paulsson lämnar rollen som CEO

09 June 2023 - (Only in Swedish) AegirBio senarelägger publicering av årsredovisningen 2022

31 May 2023 - (Only in Swedish) AEGIRBIO AVGER DELÅRSRAPPORT OCH REDOGÖR FÖR VÄSENTLIGA HÄNDELSER

30 May 2023 - (Only in Swedish) Kallelse till årsstämma i AegirBio AB (publ)

30 May 2023 - (Only in Swedish) AegirBio utser ny VD

TECHNOLOGY
ABOUT MAGNASENSE
INVESTOR RELATIONS
NEWS

SWEDEN
Magnasense AB
Scheelevägen 27
SE-223 63 Lund,
Sweden

Phone
+46 (46) 286 54 00

UK
Aegirbio UK Ltd.
3 Howard Road, St Neots
Cambridgeshire PE19 8ET
United Kingdom

Phone
+44 (0) 01480 774534

US
ABREOS BIOSCIENCES
3550 General Atomics Ct,
Bldg G02 Rm 140,
San Diego, CA 92121

Phone
+1 858 203 1169

Subscribe to our IR News Cookie policy Privacy policy

Magnasense © 2024